It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany)
to discuss the results from the maintenance phase of the True North study, investigating corticosteroid free remission in patients with ulcerative colitis treated with ozanimod.
The abstract entitled ‘142: CORTICOSTEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD: RESULTS FROM THE MAINTENANCE PHASE OF TRUE NORTH’ was presented at DDW 2021, May 21-23.
Questions:
- Could you give us a brief overview of the True North study and its findings? (0:11)
- Why is corticosteroid-free remission an important treatment goal in ulcerative colitis? (1:40)
- How were corticosteroid doses tapered in the maintenance phase of the True North study? (2:25)
- What were the results of the maintenance phase in terms of corticosteroid-free remission? (3:07)
- What are the implications of this finding, both for clinical practice and for future clinical trial design? (3:34)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist, and Falk, outside the submitted DDW work.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of DDW 2021 (Virtual).
